



**ASX Announcement**

**23 May 2025**

## **Atomo Appoints Interim Chair**

SYDNEY Australia, 23 May 2025 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) advises that the Board has appointed Mr John Kelly, the Company's current Chief Executive Officer and Managing Director, as Interim Chair of the Board.

This interim appointment follows recent changes to the composition of the Board and is considered appropriate at this time for Mr Kelly to assume the role of Chair on an interim basis to ensure continuity and stability in the leadership of the Company during this period.

The Board is committed to strong corporate governance and intends to appoint a permanent independent Chair in due course.

The Company will keep shareholders informed as further updates become available. There will be no changes to Mr Kelly's remuneration.

~ ENDS ~

**For more information, please contact:**

**John Kelly**

Managing Director & CEO & Interim Chair  
e. [john.kelly@atomodiagnostics.com](mailto:john.kelly@atomodiagnostics.com)  
p. +61 401 922 279

*This announcement was authorised by the Board.*

### **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at [www.atomodiagnostics.com](http://www.atomodiagnostics.com)